Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Novo NordiskDanish pharma; GLP-1 originator (Ozempic 2017, Wegovy 2021). CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Diabetes care leader; Novo Holdings acquired Catalent in 2024 to expand fill-finish capacity.
GLP-1 originator (Ozempic 2017, Wegovy 2021). Wegovy holds about 65% of US new prescriptions, though Lilly overtook Novo in share outside the US in early 2026. CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Novo Holdings acquired Catalent for $16.5B in 2024 to expand fill-finish capacity from 2026.